NCT05982314View on ClinicalTrials.gov

Extension Safety and Immunogenicity Study of GPNV-001

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Gamma-PN3

Experimental whole-cell pneumococcal vaccine

BIOLOGICAL

Pneumovax-23

Licensed pneumococcal vaccine

BIOLOGICAL

Prevenar-13

Licensed pneumococcal vaccine

BIOLOGICAL

Placebo

Saline placebo

Trial Locations (1)

5005

University of Adelaide, Adelaide

Sponsors

Lead Sponsor

GPN Vaccines
All Listed Sponsors
lead

GPN Vaccines

INDUSTRY

NCT05982314 - Extension Safety and Immunogenicity Study of GPNV-001 | Biotech Hunter | Biotech Hunter